On survival consumption costs: a reply to Nyman.
Lundin
Douglas
D
Swedish Pharmaceutical Benefits Board, Solna, Sweden. douglaslundin@hotmail.com
Ramsberg
Joakim
J
D003362:Cost-Benefit Analysis; D005102:Health Expenditures; D006801:Humans; D008962:Models, Theoretical; D019057:Quality-Adjusted Life Years; D017741:Survivors; D014481:United States